Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15409086 | 1.00 | HTT (0.53) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL7069557 | 0.87 | LMNA (0.52) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL31234585 | 0.85 | LDHA (0.59) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL19725366 | 0.85 | HTT (0.50) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL4005029 | 0.85 | LDHA (0.59) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL8520688 | 0.85 | LDHA (0.59) | HTTALDH1A1LDHAATMMAPT | |
| SCHEMBL12437265 | 0.83 | TDP1 (0.46) | ALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL2215260 | 0.83 | TDP1 (0.46) | ALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL19896817 | 0.83 | HTT (0.49) | HTTALDH1A1LDHAMAPTSMN1; SMN2 | |
| SCHEMBL2384186 | 0.83 | ALDH1A1 (0.52) | ALDH1A1ATMMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
| WO-2019136112-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9556178-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-21 | — | — | US | disclosed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| EP-2872514-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-05 | — | — | US | disclosed |
| US-8940736-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-16 | — | — | US | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
| EP-1734957-A4 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108675-A1 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-05-08 | — | — | US | disclosed |
| US-7309709-B2 | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1734957-A2 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097114-A2 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222223-A1 | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | HTT 3868/4885ALDH1A1 551/4885LDHA 1766/4885 |
| US-20050222223-A1 | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | APP, PSEN1, PSEN2 | HTT 5/4885ALDH1A1 1228/4885LDHA 3585/4885 |
| US-20080108675-A1 | THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | HTT 5/4885ALDH1A1 1228/4885LDHA 3585/4885 |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | HTT 4507/4885ALDH1A1 2258/4885LDHA 3635/4885 |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | HTT 4507/4885ALDH1A1 2258/4885LDHA 3635/4885 |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | HTT 4507/4885ALDH1A1 2258/4885LDHA 3635/4885 |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | HTT 4507/4885ALDH1A1 2258/4885LDHA 3635/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | HTT 3868/4885ALDH1A1 551/4885LDHA 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.